Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma

Cancer Research

Volumn 63, Issue 15, 2003, Pages 4481-4489

  Tatsumi, Tomohide ^a   Herrem, Christopher J ^a   Olson, Walter C ^a   Finke, James H ^b   Bukowski, Ronald M ^b   Kinch, Michael S ^c   Ranieri, Elena ^d   Storkus, Walter J ^a,e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MEDIMMUNE   (United States)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; EPHA2 PROTEIN; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA DR4 ANTIGEN; INTERLEUKIN 5; SYNTHETIC PEPTIDE; TRANSFORMING GROWTH FACTOR BETA; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HLA TYPING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; NUCLEOTIDE SEQUENCE; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNOLOGY; WESTERN BLOTTING;

ADULT; AGED; AMINO ACID SEQUENCE; CARCINOMA, RENAL CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-5; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; RECEPTOR, EPHA2; TRANSFORMING GROWTH FACTOR BETA;

EID: 0041589465     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Boon, T., and Old, L. J. Cancer tumor antigens. Curr. Opin. Immunol., 9: 681-683, 1997.
2. Boon, T., and van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med., 183: 725-729, 1996.
3. Boel, P., Wildmann, C., Sensi, M. L., Brasseur, R., Renauld, J. C., Coulie, P., Boon, T., and van der Bruggen, P. BAGE: a new gene encoding an antigen recognized by cytolytic T lymphocytes. Immunity, 2: 167-175, 1995.
4. Van den Eynde, B., Peeters, O., De Backer, O., Gaugler, B., Lucas, S., and Boon, T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on human melanoma. J. Exp. Med., 182: 689-698, 1995.
5. Chen, Y. T., Scanlan, M. J., Sahin, U., Tureci, O., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., and Old, L. J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA, 94: 1914-1918, 1997.
6. Brichard, V., Van Pel, A., Wolfel, T., Wolfel, C., De Plaen, E., Lethe, B., Coulie, P., and Boon, T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 178: 489-495, 1993.
7. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91: 3515-3519, 1994.
8. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P. F., Sette, A., Appella, E., and Rosenberg, S. A. Recognition of multiple epitopes in human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol., 154: 3961-3968, 1995.
9. Cheever, M. A., Disis, M. L., Bernhard, H., Gralow, J. R., Hand, S. L., Huseby, E. S., Qin, H. L., Takahashi, M., and Chen, W. Immunity to oncogenic proteins. Immunol. Rev., 145: 33-59, 1995.
10. Gnjatic, S., Cai, Z., Viguier, M., Chouaib, S., Guillet, J. G., and Choppin, J. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinoma and melanomas. J. Immunol., 160: 328-333, 1998.
11. Wolfel, T., Hauer, M., Schneider, J., Serrano, M., Wolfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Buschenfelde, K. H., and Beach, D. A p16INK4a-insesitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (Wash. DC), 269: 1281-1284, 1995.
12. Coulie, P. G., Karanikas, V., Colau, D., Lurquin, C., Landry, C., Marchand, M., Dorval, T., Brichard, V., and Boon, T. A monoclonal cytolytic T lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. USA, 98: 10290-10295, 2001.
13. Yu, J. S., Wheeler, C. J., Zeltzer, P. M., Ying, H., Finger, D. N., Lee. P. K., Yong, W. H., Incardona, F., Thompson, R. C., Riednger, M. S., Zhang, W., Prins, R. M., and Black, K. L. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res., 61: 842-847, 2001.
14. Jager, E., Gnjatic, S., Nagata, Y., Stockert, E., Jager, D., Karbach, J., Neumann, A., Rieckenberg, J., Chen, Y. T., Ritter, G., Hoffman, E., Arand, M., Old, L. J., and Knuth, A. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. USA, 97: 12198-12203, 2000.
15. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
16. Topalian, S. L., Rivoltini, L., Mancini, M., Markus, N. R., Robbins, P. F., Kawakami, Y., and Rosenberg, S. A. Human CD4+ T cells specially recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA, 91: 9461-9465, 1994.
17. Chaux, P., Vantomme, V., Stroobant, V., Thielemans, K., Corthals, J., Luiten, R., Eggermont, A., Boon, T., and van der Bruggen, P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4+ T lymphocytes. J. Exp. Med., 189: 767-777, 1999.
18. Pieper, R., Christian, R. E., Gonzales, M. I., Nishimura, M. I., Gupta, G., Settlage, R. E., Shabanowitz, J., Rosenberg, S. A., Hunt, D. F., and Topalian, S. L. Biochemical identification of a mutated human melanoma antigen recognized by CD4+ T cells. J. Exp. Med., 189: 757-765, 1999.
19. Wang, R. F., Wang, X., Atwood, A. C., Topalian, S. L., and Rosenberg, S. A. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science (Wash. DC), 284: 1351-1354, 1999.
20. Topalian, S. L., Gonzales, M. I., Parkhurst, M., Li, U. F., Southwood, S., Sette, A., Rosenberg, S. A., and Robbins, P. F. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med., 183: 1965-1971, 1996.
21. Jager, E., Jager, D., Karbach, J., Chen, Y. T., Ritter, G., Nagata, Y., Gnjatic, S., Stockert, E., Arand, M., Old, L. J., and Knuth, A. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4+ T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med., 191: 625-630, 2000.
22. Zarour, H. M., Storkus, W. J., Brusic, V., Williams, E., and Kirkwood, J. M. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res., 60: 4946-4952, 2000.
23. 51-73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells. Proc. Natl. Acad. Sci. USA, 97: 400-405, 2000.
24. Pardoll, D. M., and Topalian, S. L. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol., 10: 588-594, 1998.
25. Toes, R. E., Ossendrop, F., Offringa, R., and Melief, C. J. M. CD4+ T cells and their role in antitumor immune responses. J. Exp. Med., 189: 753-756, 1999.
26. Eph Nomenclature Committee. Unified nomenclature for Eph family receptors and their ligands. The ephrins. Cell, 90: 403-404, 1997.
27. Mellitzer, G., Xu, Q., and Willkinson, D. G. Control of cell behavior by signaling through Eph receptors and Ephrins. Curr. Opin. Neurobiol., 10: 400-408, 2000.
28. Willkinson, D. G. Multiple roles of Eph receptors and Ephrins in neural development. Nat. Rev. Neurosci., 2: 155-164, 2001.
29. Knoll, B., Zarbalis, K., Wurst, W., and Drescher, U. A role for the EphA family in the topographic targeting of vomeronasal axons. Development, 128: 895-906, 2000.
30. Oba, S., Wang, Y., Song, J., Li, Z., Kobayashi, K., Tsugane, S., Hamada, G., Tanaka, M., and Sugimura, H. Genomic structure and loss of heterozygosity of EphB2 in colorectal cancer. Cancer Lett., 164: 97-104, 2001.
31. Dodelet, V., and Pasquale, E. Eph receptors and Ephrin ligands: embryogenesis to tumorgenesis. Oncogene, 19: 5614-5619, 2000.
32. Miao, H., Burnette, E., Kinch, M., Simon, E., and Wang, B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat. Cell Biol., 2: 62-69, 2000.
33. Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., Radmacher, M., Simon, R., Yakhini, Z., Ben-Dor, A., Sampas, N., Dougherty, E., Wang, E., Marincola, F., Gooden, C., Lueders, J., Glatfelter, A., Leja, D., Dietrich, K., Beaudry, C., Berens, M., Alberts, D., and Sondak, V. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (Lond.), 406: 536-540, 2000.
34. Easty, D., Gurthrie, B., Maung, K., Farr, C., Lindberg, R., Toso, R., Herlyn, M., Benette, D. Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res., 55: 2528-2532, 1995.
35. Easty, D., Hill, S., Hsu, M., Fallowfield, M., Florenes, V., Herlyn, M., and Bennett, D. Up-regulation of Ephrin-A1 during melanoma progression. Int. J. Cancer, 84: 494-501, 1999.
36. Walker-Daniels, J., Coffman, K., Azimi, M., Rhim, J., Bostwick, D., Snyder, P., Kerns, B., Waters, D., and Kinch, M. Overexpression of the EphA2 tyrosinase kinase in prostate cancer. Prostate, 41: 275-280, 1999.
37. Zantek, N. D., Walker-Daniels, J., Stewart, J., Hansen, R. K., Robinson, D., Miao, H., Wang, B., Kung, H. J., Bissell, M. J., and Kinch, M. S. MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interaction in breast cancer. Clin. Cancer Res., 7: 3640-3648, 2001.
38. nd, Kinch, M. S., and Harpole, G. H., Jr. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann. Thorac. Surg., 72: 1144-1148, 2001.
39. Van den Hove, L. E., Van Gool, S. W., Van Poppel, H., Baert, L., Coorrevitis, L., Van Damme, B., and Ceupens, J. L. Phenotype, cytokine, production and cytolytic capacity of fresh (uncultured) tumor-infiltrating T lymphocytes in human renal cell carcinoma. Clin. Exp. Immunol., 109: 501-509, 1997.
40. Finke, J. H., Rayman, P., Hart, L., Alexander, J. P., Edinger, M. G., Tubbs, R. R., Klein, E., Tuason, L., and Bukowski, R. M. Characterization of tumor-infiltrating lymphocytes subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-γ secretion, and proliferation. J. Immunother. Emphas. Tumor Immunol., 15: 91-104, 1994.
41. Kolbeck, P. C., Kaveggia, F. F., Johansson, S. L., Grune, M. T., and Taylor. R, J. The relationships among tumor-infiltrating lymphocytes, histopathologic findings and long-term clinical follow-up in renal cell carcinoma. Mod. Pathol., 5: 420-425, 1992.
42. Maeurer, M. J., Martin, D. M., Castelli, C., Elder, E., Leder, G., Storkus, W. J., and Lotze, M. T. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshed collected tumor-infiltrating lymphocytes. Cancer Immunol. Immunother., 41: 111-121, 1995.
43. Elsasser-Beile, U., Kolble, N., Grussenmeyer, T., Schultze-Seemann, W., Wetterauer, U., Gallati, H., Schultz Monting, J., and von Kleist, S. Th1 and Th2 cytokine response patterns in leukocyte culture of patients with urinary bladder, renal call and prostate carcinoma. Tumor Biol., 19: 470-476, 1998.
44. Ryan, M. J., Johnson, G., Kirk, J., Fuerstenberg, S. M., Zager, R. A., and Torok-Storb, B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int., 45: 48-57, 1994.
45. Honeyman, M. C., Brusic, V., Stone, N. L., and Harrison, L. C. Neural network-based prediction of candidate T-cell epitope. Nat. Biotechnol., 16: 966-969, 1998.
46. Southwood, S., Sidney, J., Kondo, A., Del Guercio, M-F., Appella, E., Hoffman, S., Kubo, R. T., Chesnut, R. W., Grey, H. M., and Sette, A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol., 160: 3363-3383, 1998.
47. Tatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, J. H., Bukowski, R. M., Mueller-Berghaus, J., Kirkwood, J. M., Kwok, W. W., and Storkus, W. J. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4+ T cells responses against MAGE-6 in HLA-DRβ1*0401+ patients with renal cell carcinoma or melanoma. J. Exp. Med., 196: 619-628, 2002.
48. Keilholz, U., Weber, J., Finke, J., Gabrilovich, D., Kast, M., Disis, N., Kirkwood, J., Scheibenbogen, C., Schlom, J., Maino, V., Lyerly, K., Lee, P., Storkus, W. J., Marincola, F., Worobecand, A., and Atkins, M. B. Immunologic monitoring of cancer vaccine therapy. J. Immunother., 25: 97-138, 2002.
49. Miyazaki, T., Kato, H., Fukuchi, M., Nakajima, M., and Kuwano, H. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int. J. Cancer, 103: 657-663, 2003.
50. Ogawa, K., Pasqualini, R., Lindberg, R. A., Kain, R., Freeman, A. L., and Pasquale, E. B. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene, 19: 6043-6052, 2003.
51. Kiessling, R., Wasserman, K., Horiguchi, S., Kono, K., Sjoberg, J., Pisa, P., and Petersson, M. Tumor-induced immune dysfunction. Cancer Immunol. Immunother., 48: 353-362, 1999.
52. Liu, H., Andreansky, S., Diaz, G., Hogg, T., and Doherty, P. C. Reduced functional capacity of CD8+ T cells expanded by post-exposure vaccination of γ-herpesvirus-infected CD4-deficient mice. J. Immunol., 168: 3477-3483, 2002.
53. Moser, J. M., and Lukacher, A. E. Immunity to polyoma virus infection and tumorigenesis. Viral Immunol., 14: 199-216, 2001.
54. Krause, I., Blank, M., and Shoenfeld, Y. Immunomodulation of experimental autoimmune disease via oral tolerance. Crit. Rev. Immunol., 20: 1-16, 2000.
55. Levings, M. K., Sangregorio, R., Sartirana, C., Moschin, A. L., Battaglia, M., Orban, P. C., and Roncarolo, M. G. Human CD25+CD4+ T suppressor cell clones produce transforming growth factor β, but not interleukin 10, and are distinct from type 1 T regulatory cells. J. Exp. Med., 196: 1335-1346, 2002.
56. Vieira, P. L., de Jong, E. C., Wierenga, E. A., Kapsenberg, M. L., and Kalinski, P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J. Immunol., 164: 4507-4512, 2000.